Phase II trial of APL-1202 in patients with high risk non-muscle-invasive bladder cancer patients

Trial Profile

Phase II trial of APL-1202 in patients with high risk non-muscle-invasive bladder cancer patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2016

At a glance

  • Drugs APL 1202 (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Sponsors Asieris Pharmaceuticals
  • Most Recent Events

    • 03 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top